Trill Impact Ventures co-leads USD 25 million series B financing round in May Health
Trill Impact Ventures, announces that it together with Bpifrance, has co-led a USD 25m series B financing round in May Health, a French-American medical device company targeting Polycystic Ovary Syndrome (PCOS) related infertility. The round also saw participation from existing May Health investor Sofinnova Partners. Proceeds will advance the clinical development of May Health’s innovative device, as well as reaching CE marking that will enable market introduction in select European countries.
PCOS is the leading cause of female infertility[1], driven by lack of natural ovulation. May Health offers a novel approach to PCOS-related fertility and the upcoming REBALANCE study aims to demonstrate Ovarian Rebalancing™ as a safe and simple treatment option for activating natural ovulation.
In conjunction with the financing, Nina Rawal, Co-Head of Trill Impact Ventures and Partner at Trill Impact Advisory, will join May Health’s board of directors, and Bita Sehat, Senior Investment Director at Trill Impact Advisory, will join as an observer.
Commenting on the financing round, Nina Rawal said:
“We see May Health as a great example of a company where commercial opportunity and social impact go hand in hand. Trill Impact is excited to collaborate with the May Health team and its investors to bring their innovative product to women who have suffered from a lack of treatment options for too long.”
Anne Morrissey, CEO of May Health commented:
"For the millions of women living with PCOS, the physical and emotional impact of this condition are profound. From fertility challenges to emotional well-being and physical symptoms, women with PCOS need more viable treatment options. We are thankful to Trill Impact and Bpifrance for co-leading this financing round, and to Sofinnova Partners for their confidence in our team and for their support of our strategy to build a global Women’s Health company and to allow us to bring a solution for women with PCOS-related infertility issues.”
This material has been prepared for informational purposes only and should not be considered to be a recommendation to buy or sell securities or as investment advice. All statements and opinions included herein are subject to change as economic and market conditions dictate. There can be no assurance that any views, outlooks, or forward-looking statements will come to pass.
[1] CDC
[2] Infertility management in women with polycystic ovary syndrome: a review
SDG and Impact contribution
Polycystic ovary syndrome (PCOS) is a hormonal disorder affecting 1:10 women globally and is the leading cause of female infertility[2]. PCOS is a lifelong challenge that goes beyond fertility issues and is associated with insulin resistance, Type 2 diabetes, increased risk of cardiovascular disease, endometrial cancer as well as mental health issues such as depression and anxiety[2].
Through its products, May Health aims to contribute to several of the SDGs:
SDG 3.7 and SDG 5.6 – Ensure universal access to sexual and reproductive health-care services in accordance with ICPD and Beijing Platform for Action
SDG 3.4 – Reduce one third premature mortality from non-communicable diseases through prevention and treatment and promote mental health and well-being.
SDG 3.4.1 – Reduce mortality rate attributed to cardiovascular disease, cancer, diabetes or chronic respiratory disease.
 |  |
Related information
Trill Impact is a pioneering Impact House with around EUR 1.2 billion in assets under management across its investment strategies, Impact Private Equity, Impact Ventures and Microfinance, with a team of around 55 experienced professionals based in the Nordics, Germany, Luxembourg and USA. Trill Impact aims to become a force for positive change through impact private investments, delivering Real Returns and Lasting Impact for the benefit of investors, businesses and society at large - encouraging others to follow.
May Health is a clinical-stage medical device company committed to developing treatment options for women living with PCOS. The company is currently investigating its Ovarian Rebalancing™ treatment in clinical studies. Ovarian Rebalancing is a novel approach to PCOS-related fertility that has the potential to be a safe, straightforward option for activating natural ovulation. May Health is led by a team of serial medtech and women’s health entrepreneurs and executives with extensive experience in product development, validation, and launch. The company was founded in 2017 by Sofinnova Partners’ medtech acceleration team, MD Start. May Health is headquartered in Paris. For more information, visit www.mayhealth.com.
